Pete Stavropoulos

Stock Analyst at Cantor Fitzgerald

(3.87)
# 1,946
Out of 5,136 analysts
86
Total ratings
39%
Success rate
10.8%
Average return

Stocks Rated by Pete Stavropoulos

Novavax
Nov 5, 2026
Reiterated: Buy
Price Target: $18
Current: $8.06
Upside: +123.33%
Vera Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $100
Current: $26.97
Upside: +270.78%
Axsome Therapeutics
Nov 2, 2026
Reiterated: Buy
Price Target: $272
Current: $137.01
Upside: +98.53%
Acumen Pharmaceuticals
Oct 30, 2026
Downgraded: Sell
Price Target: n/a
Current: $0.216
Upside: -
Rezolute
Oct 5, 2026
Upgraded: Buy
Price Target: n/a
Current: $3.58
Upside: -
Nuvectis Pharma
Aug 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $19.11
Upside: -
ProMIS Neurosciences
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $3.31
Upside: +1,100.91%
Alector
Apr 15, 2026
Upgraded: Buy
Price Target: n/a
Current: $2.57
Upside: -
Alkermes
Mar 11, 2026
Reiterated: Buy
Price Target: $43
Current: $46.53
Upside: -7.59%
CervoMed
Dec 18, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $1.67
Upside: -
Reiterated: Buy
Price Target: n/a
Current: $89.55
Upside: n/a
Reiterated: Buy
Price Target: n/a
Current: $1.97
Upside: n/a
Downgraded: Hold
Price Target: n/a
Current: $11.77
Upside: n/a
Initiated Coverage: Buy
Price Target: n/a
Current: $22.61
Upside: n/a
Reiterated: Buy
Price Target: n/a
Current: $8.31
Upside: n/a
Reiterated: Buy
Price Target: n/a
Current: $3.57
Upside: n/a
Initiated Coverage: Hold
Price Target: n/a
Current: $0.6932
Upside: n/a
Initiated Coverage: Buy
Price Target: n/a
Current: $1.63
Upside: n/a
Reiterated: Buy
Price Target: $34
Current: $7.70
Upside: n/a
Rated: Hold
Price Target: n/a
Current: $17.61
Upside: n/a